Table 2 Clinicopathological characteristics and associations with MET immunoexpression in 86 primary localized myxofibrosarcomas
Number of cases (%) | MET expression index | P-value | |
|---|---|---|---|
MET expression | |||
Low expression (<30%) | 28 (32.6) | ||
Overexpression (≥30) | 58 (67.4) | ||
Sex | 0.917 | ||
Male | 47 (54.7) | 44.47±29.456 | |
Female | 39 (45.3) | 45.13±28.435 | |
Age (years) (median: 64, range 16 to 84) | 0.268, r=0.053 | ||
≤40 | 10 (10.5) | ||
41–50 | 9 (10.5) | ||
51–60 | 15 (17.4) | ||
61–70 | 29 (33.7) | ||
>70 | 23 (26.7) | ||
Location | 0.961 | ||
Extremity | 66 (76.7) | 44.85±29.560 | |
Axial | 20 (23.3) | 44.50±26.994 | |
Tumor depth | 0.004* | ||
Superficial | 33 (38.4) | 33.94±27.776 | |
Deep | 53 (61.6) | 52.31±27.269 | |
Tumor size | 0.003*, r=0.323 | ||
<6 cm | 42 (50.6) | ||
≥6 cm | 41 (49.4) | ||
Unknown | 3 | ||
Mitotic rate (per 10 high power fields) | 0.008*, r=0.285 | ||
≤9 | 50 (58.1) | ||
10–19 | 20 (23.3) | ||
≥20 | 16 (18.6) | ||
% of tumor necrosis | <0.001*, r=0.391 | ||
0% | 52 (60.5) | ||
<10% | 7 (8.1) | ||
10–49% | 25 (29.1) | ||
≥50% | 2 (2.3) | ||
% of myxoid area | <0.001*, r=-0.452 | ||
10–25% | 8 (9.3) | ||
25–49% | 28 (32.6) | ||
50–74% | 25 (29.1) | ||
≥75% | 25 (32.6) | ||
FNCLCC grade | 0.001* | ||
Grade 1 | 39 (45.3) | 32.05±26.732 | |
Grade 2 | 34 (39.5) | 53.82±27.110 | |
Grade 3 | 13 (15.1) | 59.23±26.904 | |
AJCC stage | <0.001* | ||
Stage I | 15 (18.1) | 20.67±18.504 | |
Stage II | 34 (41.0) | 41.32±27.367 | |
Stage III | 34 (41.0) | 59.71±26.854 | |
Unknown | 3 | ||
